Himalaya Nutravedics India Ltd
Himalaya Nutravedics India Q2 FY27 investor presentation: Revenue & Margins
Q2 FY27 investor presentation: what the company reported on revenue, margins and projects.
Based on Himalaya Nutravedics India Ltd's Q2 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). EBITDA for FY26: ₹810.3 lakhs, up 171.0% YoY from ₹299.0 lakhs in FY25.
From Himalaya Nutravedics India Ltd's Q2 FY27 earnings-call transcript · updated 17 Oct 2026.
Revenue & Sales Performance
- Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4).
- No explicit sales volume figures or quarterly breakdowns provided; focus is on annual financials.
- EBITDA and PAT also show strong YoY growth: EBITDA ₹810.3 lakhs (+171.0%), PAT ₹739.0 lakhs (+231.1%) (Page 22, 14, 5, 4).
- Outlook includes strategic plans to scale D2C and omni-channel presence to drive revenue growth (Page 20).
- Planned investment of ₹750 lakhs in branding and digital marketing to boost customer acquisition and hence revenue (Page 20).
- Expanding own-branded portfolio to increase high-margin SKU sales (Page 20).
2 more points from Himalaya Nutravedics India Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Himalaya Nutravedics India Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The presentation does not explicitly mention any specific capex amounts or detailed plans for capacity expansion or new plant construction.
- Manufacturing is conducted at a single integrated WHO-GMP certified facility in Hyderabad, Telangana, with no capital work-in-progress reported as of FY26.
- Capacity utilization has increased significantly at the existing plant (e.g., medicated oil utilization at 90.2% in FY26), implying enhanced utilization rather than new capacity.
2 more points from Himalaya Nutravedics India Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Himalaya Nutravedics India Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Continue your research
Others in Pharmaceuticals & Biotechnology this season
- Bajaj Healthcare (Q2 FY27)
Operating Margin: Operating Margin = (EBITDA / Revenue from operations) × 100 = (2,770.29 / 14,791.49) × 100 ≈ 18.73% . Key results statement takeaways from Baj
- Granules India (Q2 FY27)
Granules plans to invest about ₹2,000 crore in organic capital expenditure over the next 3-4 years. Key concall takeaways from Granules India Ltd's Q2 FY27…
- Solara Active (Q2 FY27)
417.34 Crores, up from Rs. Key results statement takeaways from Solara Active Pharma Sciences Ltd's Q2 FY27 results statement — and how it ranks against sector
- Accent Microcell (Q2 FY27)
. Key investor presentation takeaways from Accent Microcell Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.
Arthneeti Pro · Annual
Himalaya Nutravedics India Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Himalaya Nutravedics India Ltd Q2 FY27 results?
Reported revenue from operations for FY26: ₹4,306.8 lakhs, a year-on-year increase of 105.1% from ₹2,099.7 lakhs in FY25 (Page 22, 14, 5, 4). EBITDA for FY26: ₹810.3 lakhs, up 171.0% YoY from ₹299.0 lakhs in FY25.
What is Himalaya Nutravedics India Ltd share price analysis?
Himalaya Nutravedics India Ltd currently shows a neutral. The stock trades at a P/E of 14.7 with a market cap of ₹109 Cr. Investors should review the full earnings analysis for detailed insights.
Is Himalaya Nutravedics India Ltd planning capital expenditure?
The presentation does not explicitly mention any specific capex amounts or detailed plans for capacity expansion or new plant construction.
Keep Himalaya Nutravedics India Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.